Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ITGB8 antisense RNA 1 (ITGB8-AS1)
- Target
- ITGB8-AS1
- Molecular classification
- Long non-coding RNA, Antisense RNA, Competing endogenous RNA (ceRNA)
01
Overview
ITGB8 antisense RNA 1 (ITGB8-AS1) is a long non-coding RNA that functions as a competing endogenous RNA (ceRNA), regulating genes involved in cell adhesion and proliferation, notably in colorectal cancer. It exerts its effects by sponging tumor-suppressive microRNAs (e.g., miR-33b-5p, let-7c-5p/let-7d-5p), thereby upregulating integrin family members such as ITGA3 and ITGB3 and promoting downstream focal adhesion signaling. High expression of ITGB8-AS1 is associated with poor prognosis and advanced disease stage in CRC, and suppression via antisense oligonucleotides inhibits tumor growth in preclinical models. Its presence in plasma makes it a promising biomarker for CRC diagnosis and monitoring.
- Other names
- ITGB8 antisense RNA 1ITGB8-AS1CTA-293F17.1
02
Mechanism of action
Antisense oligonucleotide-mediated knockdown, reducing ITGB8-AS1 levels and suppressing CRC cell growth/tumor formation. Modulation of integrin-regulated focal adhesion and downstream signaling (SRC, ERK, p38 MAPK phosphorylation).
03
Biological functions
Regulation of cell proliferationTumor growth and progressionFocal adhesion signalingmiRNA sponging (e.g., miR-33b-5p, let-7c-5p, let-7d-5p)
04
Disease associations
Cancer (especially colorectal cancer)Potential for roles in other solid tumors, though CRC is most studied
05
Safety considerations
No clinical safety data available; antisense oligonucleotide therapies generally require careful assessment for off-target effects and immunogenicity
06
Interacting drugs
Antisense oligonucleotides targeting ITGB8-AS1 in preclinical studies
1 more in the full profile.
07
Biomarkers
Circulating ITGB8-AS1 RNA levels (in plasma) correlate with CRC stage, differentiation, and prognosis
Beyond the preview
Go deeper on ITGB8 antisense RNA 1 (ITGB8-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITGB8 antisense RNA 1 (ITGB8-AS1).